Dianthus Therapeutics (DNTH) Operating Margin (2022 - 2025)
Dianthus Therapeutics' (DNTH) quarterly Operating Margin came in at 10173.74% in Q3 2025, down 879713.0% year-on-year from N/an in Q3 2024, and up 43.78% quarter-over-quarter from 18096.89% in Q2 2025.
Dianthus Therapeutics (DNTH) Operating Margin (2022 - 2025) Analysis & Trends
Dianthus Therapeutics' Operating Margin history runs 4 years deep, the most recent figure standing at 10173.74% for Q3 2025.
- On a quarterly basis, Operating Margin fell 879713.0% year-over-year to 10173.74% in Q3 2025; TTM through Sep 2025 was 4504.27%, a 295928.0% decrease from a year earlier, with the FY2024 full-year figure at 1633.74%, up 7093.0% from the prior year.
- Operating Margin improved to 10173.74% in Q3 2025 per DNTH's latest filing, from 18096.89% in the prior quarter.
- Across five years, Operating Margin topped out at 703.67% in Q3 2022 and bottomed at 18096.89% in Q2 2025.
- The 4-year median for Operating Margin is 1705.52% (2023), against an average of 3618.15%.
- Across the five-year window, Operating Margin jumped 42807 bps in 2024 and tumbled 1690505 bps in 2025, its largest moves.
- Year by year, Operating Margin stood at 910.04% in 2022, then plunged by 212 bps to 2835.01% in 2023, then grew by 15 bps to 2406.94% in 2024, then sank by 323 bps to 10173.74% in 2025.
- Per Business Quant, the three latest DNTH Operating Margin figures stand at 10173.74% (Q3 2025), 18096.89% (Q2 2025), and 2764.75% (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Dianthus Therapeutics | 3.37 Bn | 2.97 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -10,173.74% |
| Jun 30, 2025 | -18,096.89% |
| Mar 31, 2025 | -2,764.75% |
| Dec 31, 2024 | -2,406.94% |
| Sep 30, 2024 | -1,376.61% |
| Jun 30, 2024 | -1,191.84% |
| Mar 31, 2024 | -2,041.65% |
| Dec 31, 2023 | -2,835.01% |
| Sep 30, 2023 | -1,705.52% |
| Jun 30, 2023 | -1,215.27% |
| Mar 31, 2023 | -1,614.08% |
| Dec 31, 2022 | -910.04% |
| Sep 30, 2022 | -703.67% |